FIELD: immunology.
SUBSTANCE: present invention relates to immunology. Disclosed are an antibody and its antigen-binding fragment capable of specific binding to a segment of the beta chain of the TRBV9 family of the human T-cell receptor. Also disclosed are nucleic acids, expression vectors, a method for producing a host cell, a host cell, a method for producing an antibody or an antigen-binding fragment thereof and pharmaceutical compositions. What is also described is a method for inhibiting the biological activity of the T-cell receptor, a method of treating a disease or disorder mediated by a human T-cell receptor, and using the antibody or pharmaceutical composition.
EFFECT: present invention can find further application in therapy of various conditions, particularly celiac disease, T-cell leukemia and T-cell lymphoma.
20 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODIES WHICH SPECIFICALLY BIND TO THE BETA-CHAIN REGION OF THE TRBV-9 FAMILY OF THE HUMAN T-CELL RECEPTOR, AND METHODS FOR USE THEREOF | 2018 |
|
RU2711871C1 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
